Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares
January 13 2021 - 6:15AM
Heidelberg, Germany, January 13, 2021 – Affimed
N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer, today announced the pricing of its
previously announced public offering of 16,666,667 of its common
shares at a public offering price of $6.00 per common share. In
addition, Affimed has granted the underwriters a 30-day
over-allotment option to purchase up to 2,500,000 common shares at
the public offering price less underwriting discounts. After
deducting the underwriting discounts, the net proceeds of the
public offering are expected to be approximately $94 million. The
offering is expected to close on or about January 15, 2021, subject
to customary closing conditions.
Jefferies LLC, SVB Leerink LLC and Credit Suisse
Securities (USA) LLC are acting as joint book-running managers and
Laidlaw & Company (UK) Ltd. is acting as co-manager. A shelf
registration statement relating to these securities filed with the
Securities and Exchange Commission (the “SEC”) was declared
effective by the SEC on December 30, 2020. The offering will be
made only by means of a prospectus and prospectus supplement. A
preliminary prospectus supplement and accompanying prospectus
related to the offering have been filed with the SEC and are
available at the SEC’s website located at www.sec.gov. A final
prospectus supplement and accompanying prospectus will be filed
with the SEC. Copies of the preliminary prospectus supplement and
accompanying prospectus related to the offering may be obtained by
contacting Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or
by telephone at (877) 821-7388 or by email at
Prospectus_Department@Jefferies.com, SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at (800) 808-7525 ext. 6132, or by email at
syndicate@svbleerink.com, or Credit Suisse Securities (USA) LLC,
Attention: Prospectus Department, 6933 Louis Stephens Drive,
Morrisville, NC 27560, by telephone at (800) 221-1037, or by email
at usa.prospectus@credit-suisse.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of, these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer. Affimed’s fit-for-purpose ROCK®
platform allows innate cell engagers to be designed for specific
patient populations. The company is developing single and
combination therapies to treat hematologic and solid tumors. The
company is currently enrolling patients into a
registration-directed study of AFM13 for CD30-positive
relapsed/refractory peripheral T cell lymphoma and into a Phase
1/2a dose escalation/expansion study of AFM24 for the treatment of
advanced EGFR-expressing solid tumors.
Forward-looking Statements
This press release contains statements that
constitute “forward-looking statements,” including with respect to
the proposed offering of common shares and the anticipated use of
the net proceeds. No assurance can be given that the offering
discussed above will be completed on the terms described, or at
all, or that the net proceeds of the offering will be used as
indicated. Forward-looking statements are subject to numerous
conditions, many of which are beyond the control of the company,
including those set forth in the Risk Factors section of the
company’s registration statement and preliminary prospectus for the
company’s offering filed with the Securities and Exchange
Commission (“SEC”). Copies are available on the SEC’s website,
www.sec.gov. The company undertakes no obligation to update these
statements for revisions or changes after the date of this release,
except as required by law.
Affimed Investor and Media
Contact:Alexander Fudukidis, Head of Investor
RelationsE-Mail: a.fudukidis@affimed.com, IR@affimed.comTel.: +1
(917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024